S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:AFMD

Affimed News Headlines

$6.52
-0.06 (-0.91 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.23
Now: $6.52
$6.59
50-Day Range
$5.62
MA: $6.42
$7.20
52-Week Range
$1.42
Now: $6.52
$7.48
Volume1.54 million shs
Average Volume2.17 million shs
Market Capitalization$575.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81

Headlines

Affimed (NASDAQ AFMD) News Headlines Today

Source:
SourceHeadline
Affimed (NASDAQ:AFMD) PT Raised to $9.00 at SVB LeerinkAffimed (NASDAQ:AFMD) PT Raised to $9.00 at SVB Leerink
marketbeat.com - November 11 at 7:27 AM
Affimed (NASDAQ:AFMD) Lifted to Hold at BidaskClubAffimed (NASDAQ:AFMD) Lifted to Hold at BidaskClub
marketbeat.com - August 21 at 1:24 AM
Affimed (NASDAQ:AFMD)  Shares Down 5.6% Affimed (NASDAQ:AFMD) Shares Down 5.6%
americanbankingnews.com - January 21 at 8:02 PM
Aphria (APHA) Looks Good: Stock Adds 6% in Session - NasdaqAphria (APHA) Looks Good: Stock Adds 6% in Session - Nasdaq
nasdaq.com - January 15 at 12:55 PM
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo FinanceAffimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance
finance.yahoo.com - January 15 at 12:55 PM
Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares - Yahoo FinanceAffimed Announces Pricing of $100,000,000 Public Offering of Common Shares - Yahoo Finance
finance.yahoo.com - January 15 at 12:55 PM
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional SharesAffimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 15 at 12:55 PM
BlackRock (BLK) Q4 Earnings and Revenues Top Estimates - NasdaqBlackRock (BLK) Q4 Earnings and Revenues Top Estimates - Nasdaq
nasdaq.com - January 15 at 7:54 AM
Will Mortgage Banking Support Wells Fargo (WFC) Q4 Earnings? - NasdaqWill Mortgage Banking Support Wells Fargo (WFC) Q4 Earnings? - Nasdaq
nasdaq.com - January 14 at 9:54 PM
Affimed (AFMD) Catches Eye: Stock Jumps 8.8% - Yahoo FinanceAffimed (AFMD) Catches Eye: Stock Jumps 8.8% - Yahoo Finance
finance.yahoo.com - January 14 at 4:53 PM
Affimed (NASDAQ:AFMD) Reaches New 52-Week High at $7.47Affimed (NASDAQ:AFMD) Reaches New 52-Week High at $7.47
americanbankingnews.com - January 13 at 1:44 PM
Affimed Announces Pricing of $100000000 Public Offering of Common Shares - GlobeNewswireAffimed Announces Pricing of $100000000 Public Offering of Common Shares - GlobeNewswire
globenewswire.com - January 13 at 8:23 AM
Affimed Announces Pricing of $100,000,000 Public Offering of Common SharesAffimed Announces Pricing of $100,000,000 Public Offering of Common Shares
finance.yahoo.com - January 13 at 8:22 AM
Affimed N.V. initiates equity offering - Seeking AlphaAffimed N.V. initiates equity offering - Seeking Alpha
seekingalpha.com - January 12 at 7:53 PM
Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo FinanceAffimed to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
finance.yahoo.com - January 11 at 9:03 AM
Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank - GlobeNewswireAffimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank - GlobeNewswire
globenewswire.com - January 11 at 9:03 AM
Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley BankAffimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank
finance.yahoo.com - January 11 at 9:03 AM
Affimed to Present at the 39th Annual J.P. Morgan Healthcare ConferenceAffimed to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 11 at 9:03 AM
12 Health Care Stocks Moving In Fridays After-Market Session - Benzinga12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
benzinga.com - January 8 at 5:46 PM
Affimed (NASDAQ:AFMD) Trading Up 8.8%Affimed (NASDAQ:AFMD) Trading Up 8.8%
americanbankingnews.com - January 7 at 7:26 PM
Affimed updates on clinical studies and cash balances - Seeking AlphaAffimed updates on clinical studies and cash balances - Seeking Alpha
seekingalpha.com - January 7 at 4:36 PM
Affimed (AFMD) Announces Pipeline and Business Update - StreetInsider.comAffimed (AFMD) Announces Pipeline and Business Update - StreetInsider.com
streetinsider.com - January 7 at 4:36 PM
Affimed Announces Pipeline and Business Update Nasdaq:AFMD - GlobeNewswireAffimed Announces Pipeline and Business Update Nasdaq:AFMD - GlobeNewswire
globenewswire.com - January 7 at 11:09 AM
Affimed Announces Pipeline and Business UpdateAffimed Announces Pipeline and Business Update
finance.yahoo.com - January 7 at 11:09 AM
 Brokerages Anticipate Affimed (NASDAQ:AFMD) to Announce -$0.01 EPS Brokerages Anticipate Affimed (NASDAQ:AFMD) to Announce -$0.01 EPS
americanbankingnews.com - December 29 at 11:16 AM
Affimed NVAffimed NV
bloomberg.com - December 24 at 10:33 PM
Affimeds Stockpile Of Partnerships Supports A Long-Term Investment - Seeking AlphaAffimed's Stockpile Of Partnerships Supports A Long-Term Investment - Seeking Alpha
seekingalpha.com - December 19 at 9:56 AM
Affimeds Stockpile Of Partnerships Supports A Long-Term InvestmentAffimed's Stockpile Of Partnerships Supports A Long-Term Investment
seekingalpha.com - December 19 at 8:53 AM
Is AFMD A Good Stock To Buy Now? - Yahoo FinanceIs AFMD A Good Stock To Buy Now? - Yahoo Finance
finance.yahoo.com - December 16 at 12:00 AM
Is AFMD A Good Stock To Buy Now?Is AFMD A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 12:00 AM
Outlook on the Trispecific Antibodies Global Market to 2024 - Featuring AbbVie, Affimed and Biotheus Among Others - GlobeNewswireOutlook on the Trispecific Antibodies Global Market to 2024 - Featuring AbbVie, Affimed and Biotheus Among Others - GlobeNewswire
globenewswire.com - December 10 at 4:41 PM
Outlook on the Trispecific Antibodies Global Market to 2024 - Featuring AbbVie, Affimed and Biotheus Among Others - Yahoo FinanceOutlook on the Trispecific Antibodies Global Market to 2024 - Featuring AbbVie, Affimed and Biotheus Among Others - Yahoo Finance
finance.yahoo.com - December 10 at 8:58 AM
Affimed (AFMD) Announces Updated AFM13 Clinical Data Presentation at ASH - StreetInsider.comAffimed (AFMD) Announces Updated AFM13 Clinical Data Presentation at ASH - StreetInsider.com
streetinsider.com - December 7 at 5:07 PM
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma - GlobeNewswireAffimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma - GlobeNewswire
globenewswire.com - December 7 at 5:07 PM
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive LymphomaAffimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma
finance.yahoo.com - December 7 at 5:07 PM
Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSDs anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood - GlobeNewswireAffimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood - GlobeNewswire
globenewswire.com - November 19 at 6:29 PM
Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in BloodAffimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood
finance.yahoo.com - November 19 at 6:29 PM
Growth Investors: Industry Analysts Just Upgraded Their Affimed N.V. (NASDAQ:AFMD) Revenue Forecasts By 20% - NasdaqGrowth Investors: Industry Analysts Just Upgraded Their Affimed N.V. (NASDAQ:AFMD) Revenue Forecasts By 20% - Nasdaq
nasdaq.com - November 11 at 8:20 PM
Affimed N.V. (AFMD) Q3 2020 Earnings Call Transcript - Motley FoolAffimed N.V. (AFMD) Q3 2020 Earnings Call Transcript - Motley Fool
fool.com - November 11 at 8:27 AM
Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates - Yahoo FinanceAffimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
finance.yahoo.com - November 10 at 6:35 PM
Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript - Seeking AlphaAffimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 6:35 PM
Affimed N.V. (AFMD) Q3 2020 Earnings Call TranscriptAffimed N.V. (AFMD) Q3 2020 Earnings Call Transcript
fool.com - November 10 at 2:49 PM
Affimed: Q3 Earnings InsightsAffimed: Q3 Earnings Insights
benzinga.com - November 10 at 1:35 PM
Affimed jumped 10% after Q3 beat, robust growth in top-line of 402%Affimed jumped 10% after Q3 beat, robust growth in top-line of 402%
seekingalpha.com - November 10 at 1:35 PM
Affimed N.V.s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call TranscriptAffimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript
seekingalpha.com - November 10 at 1:35 PM
Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue EstimatesAffimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates
nasdaq.com - November 10 at 1:35 PM
ARNA Falls Short Of ADVICE, PFEs COVID-19 Vaccine Shows 90% Efficacy, SUPN Hit By Double Whammy - NasdaqARNA Falls Short Of ADVICE, PFE's COVID-19 Vaccine Shows 90% Efficacy, SUPN Hit By Double Whammy - Nasdaq
nasdaq.com - November 10 at 8:34 AM
Affimed EPS beats by €0.01, beats on revenue - Seeking AlphaAffimed EPS beats by €0.01, beats on revenue - Seeking Alpha
seekingalpha.com - November 10 at 8:34 AM
Affimed Earnings Preview - Yahoo FinanceAffimed Earnings Preview - Yahoo Finance
finance.yahoo.com - November 10 at 8:34 AM
Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress - GlobeNewswireAffimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress - GlobeNewswire
globenewswire.com - November 10 at 8:34 AM
Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational ProgressAffimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress
finance.yahoo.com - November 10 at 8:34 AM
ARNA Falls Short Of ADVICE, PFEs COVID-19 Vaccine Shows 90% Efficacy, SUPN Hit By Double Whammy ARNA Falls Short Of ADVICE, PFE's COVID-19 Vaccine Shows 90% Efficacy, SUPN Hit By Double Whammy
rttnews.com - November 10 at 3:14 AM
This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.